Market Overview

UPDATE: Wedbush Raises PT to $32 on Pacira Pharmaceuticals on Long-Term Outlook

Share:
Related PCRX
Pacira Announces Data Reinforcing Benefits of EXPAREL for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery
Wedbush Securities Believes SH Data Bodes Well For Pacira Pharmaceuticals
The Vetr community has downgraded $PCRX to 3-Stars (Vetr)

Wedbush maintained Pacira Pharmaceuticals (NASDAQ: PCRX) with an Outperform rating and raised the price target from $23.00 to $32.00.

Wedbush said, "As already preannounced, PCRX reported Q4 EXPAREL sales of $7.8MM, ahead of our original $7.0MM estimate. Q4 total revenues were $10.5MM and GAAP EPS loss was ($0.50) versus our ($0.32) and Street's ($0.42) estimates. The company ended Q4 with about $42.6MM in cash and including proceeds from the January convertible debt offering, we estimate current cash of about $123MM. We project runway well into potential profitability, which we model to occur in 2014."

Pacira Pharmaceuticals closed at $25.30 on Wednesday.

Latest Ratings for PCRX

DateFirmActionFromTo
Mar 2015BarclaysMaintainsOverweight
Mar 2015Canaccord GenuityMaintainsBuy
Mar 2015BarclaysMaintainsOverweight

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

Around the Web, We're Loving...